Navigation Links
AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
Date:4/8/2013

Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy.

"Basically what we're trying to do is use triple-negative breast cancer models to develop targeted drugs for treatment. Paragazole is an especially exciting candidate," says Jennifer Diamond, MD, investigator at the University of Colorado Cancer Center and medical oncologist at the University of Colorado Hospital.

Paragazole is a novel histone deacetylase (HDAC) inhibitor developed at CU Boulder in the laboratories of Xuedong Liu and Andy Phillips, being tested at the CU Cancer Center. In this study, Diamond and colleagues tested the drug against a range of breast cancer cell lines with and without combination with chemotherapies paclitaxel, gemcitabine or carboplatin. Interestingly, it was specifically the cell lines that didn't express estrogen the aggressive, triple-negative cells that were most affected by paragazole. Sure enough, the researchers saw increased expression of CARM1 mediated estrogen receptors in these especially sensitive cells.

It was as if paragazole set up these triple negative cells so that chemotherapy could be more effective.

"This really is a case in which the result was greater than the sum of its parts. Paragazole with chemotherapy was more effective than the combined effects of both drugs, alone," Diamond says.

Studies with the drug are continuing with the eventual goal of moving the therapy from the lab to the clinic in selected patients.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1

Related biology news :

1. REACH news: European ombudsman takes up PETA complaint
2. Good news: Fewer maternal and child deaths
3. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
4. Preclinical studies use specialized ultrasound to detect presence of cancer
5. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
6. Cleverly designed vaccine blocks H5 avian influenza in models
7. Pig brain models provide insights into human cognitive development
8. Engineering control theory helps create dynamic brain models
9. Mentoring models to move minorities to majorities in STEM
10. Transplanted neural stem cells slows als onset and progression in mouse models
11. Improving the development of new cancer models using an advanced biomedical imaging method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... America (GSA) and the American Society for Cell Biology (ASCB) ... Sciences Education ( LSE ). This partnership adds ... of educational resources and research to its members and the ... education research in the life sciences and is renowned for ...
... researchers led by Charles D. Nichols, PhD, Associate Professor ... has successfully translated a new technology to better study ... genetic tool Designer Receptors Exclusively Activated by ... and dose-dependently remotely control behaviors and physiological processes in ...
... of Colorado School of Medicine and Children,s Hospital Colorado ... inability to process Vitamin B12. The disorder is ... inherited conditions cannot process vitamin B 12 properly," says ... author of a paper about the new disease. "These ...
Cached Biology News:Genetics Society of America joins editorial partnership for CBE-Life Sciences Education 2LSUHSC researchers develop new system to better study behavior, cell function 2Peering into genetic defects, CU scientists discover a new metabolic disease 2Peering into genetic defects, CU scientists discover a new metabolic disease 3
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... SPRINGS, Florida , August 26, 2015 /PRNewswire/ ... of the biggest factors fueling the optimism in ... approvals, M&A,s, collaborations and life sciences advancements.  Active ... developments are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, ... (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech ... R&D capability and technology platform company serving the pharmaceutical, ... Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), ... Kong with 20 years of operations in ... two companies have signed an agreement whereby WuXi,s Laboratory ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
... g Blocking Reagent , 2 x 50 ml 10X ... , 0.2 ml BL21 glycerol stock , 0.2 ... stock , 1010 pfu T7Select Positive Control Lysate , ... l S-protein HRP Conjugate , 2 ml T7Select S-protein ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... designed for ultra-sensitive detection of primary ... membranes. Since all necessary reagents are ... the WesternBreeze Kits save you time ... getting your final results. Solutions are ...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
Biology Products: